Journals / Turkish Journal of Surgery / 2018 / Cilt: 34 - Sayı: 4

Gastrointestinal stromal tumors: A clinical and histopathological presentation of 27 cases

Pages
259–263
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The size, mitotic index, and Ki-67 values were to be found high in intermediate- and high-riskgroups and metastatic diseases.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors that express type 3 tyrosine kinasereceptors and are thought to develop from the neoplastic transformation of the interstitial Cajal cells.
📊
Key Findings & Data:The presentstudy was performed to morphologically and immunohistologically evaluate GISTs, to compare their qualities usinga GIST risk categorization system, and to identify the diagnostic and prognostic parameters of GISTs.Material and Methods: A total of 27 patients with GISTs underwent treatment and were followed up at the Gaziosmanpaşa Taksim Training and Research Hospital.
💡
Conclusion & Impact:The size, mitotic index, and Ki-67 values were to be found high in intermediate- and high-riskgroups and metastatic diseases.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objective: Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors that express type 3 tyrosine kinasereceptors and are thought to develop from the neoplastic transformation of the interstitial Cajal cells. The presentstudy was performed to morphologically and immunohistologically evaluate GISTs, to compare their qualities usinga GIST risk categorization system, and to identify the diagnostic and prognostic parameters of GISTs.Material and Methods: A total of 27 patients with GISTs underwent treatment and were followed up at the Gaziosmanpaşa Taksim Training and Research Hospital. Descriptive statistics was used to calculate the mean and medianvalues. Survival analysis was performed by the Kaplan–Meier method. The analyses were performed using the SPSSversion 22.0 software.Results: The mean follow-up time was 3.5 (5 months to 13 years) years. The mean age was 60.4 (29–82) years. The tumors were localized in the stomach (62.9%), extraintestinal areas (14.8%), intestine (7.4%), esophagus (7.4%), and rectum (7.4%). Twenty-four patients were classified according to the Fletcher system. Of these patients, 7 (25.9%) wereclassified as very low risk, 8 (29.6%) as low risk, 7 (25.9%) as intermediate risk, and 2 (7.4%) as high risk. Twenty-fourpatients underwent surgery. Of the 3 patients who did not undergo surgery, 1 had metastatic disease at the time ofdiagnosis, and 2 had mini- or micro-GISTs in the stomach. On endoscopic surveillance, all tumors remained stable.Three out of the 27 patients were lost to follow-up. Two patients developed recurrence, and 1 patient died of GIST.Conclusion: We analyzed the clinical and pathological characteristics of GIST. The most common site of tumor originwas the stomach. The size, mitotic index, and Ki-67 values were to be found high in intermediate- and high-riskgroups and metastatic diseases.

🔖

Cite This Article

GÖNÜLLÜ, D., DEMİRAY, O., İLGÜN, S., YILDIZ, U. M., GEDİK, M. L., ER, M., İĞDEM, A., KIMILOĞLU, E., KÖKSOY, F. N. (2018). Gastrointestinal stromal tumors: A clinical and histopathological presentation of 27 cases. Turkish Journal of Surgery, Cilt: 34 - Sayı: 4, 259–263. https://ajindex.com/articles/376567

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Pidhoreeky I, Chency RT, Kraybill WG, Gibbs JF. Gastrointestinal stromal tumors:current diagnosis, biologic behavior, and management. Ann Surg Oncol 2000: 7; 705-712. [CrossRef] Valsangkar N, Sehdev A, Misra S, Zimmers TA, O’Neil BH, Koniaris LG. Current management of gastrointestinal stromal tumors: Surgery, current biomarkers, mutations, and therapy. Surgery 2015; 158: 1149-1164. [CrossRef] Lai EC, Lau SH, Lau WY. Current management of gastrointestinal stromal tumors-A comprehensive review. Int J Surg 2012; 10: 334-340. [CrossRef] Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of Gastrointestinal Stromal Tumors: A consensus Approach. Human Pathology 2002; 33: 459-465. [CrossRef] Neeta Somaiah. Gastrointestinal stromal tumors: optimizing therapy throughout the course of disease. Available from URL: www.clinicaloptions.com/oncology. 2015
  2. Lasota J, Corless CL, Heinrich MC, Debiec-Rychter M, Sciot R, Wardelmann E, et al. Maria Debiec-Rychter, Sciot R, Eva W. Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod Pathol 2008; 21: 476-484. [CrossRef] Taniguchi M, Nishida T, Hirota S, Isozaki K, Ito T, Nomura T, et al. Effect of c-kit Mutation on Prognosis of Gastrointestinal Stromal Tumors. Cancer Res 1999; 59: 4297-4300. Anna Nasierowska-Guttmejer. Gastrointestinal stromal tumors. In Rutkowski P, ed. Soft Tissue Sarcomas. Copyright Via Media: 2016, p: 126-52. Gabriella A. Expression profiling of gastrointestinal stromal tumors biomarkers for prognosis and therapy (MSD Thesis). University of Gothenburg; 2012. Local treatment for gastrointestinal stromal tumors. Available from URL: www.up to date.com Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol 2002: 10: 81-89. [CrossRef] Thomas RM, SobinLH. Gastrointestinal cancer incidence and prognosis by histologic type, SEER population based data 1973- 1983. Cancer 1995: 75; 154-170. [CrossRef] Michael S, Emmanouel D, Charikleia S, Panagiotis S, Electra P, Georgia L, Michael S. Gastrointestinal stromal tumor. W J of Surg Oncol 2009; 7: 61. [CrossRef] Ortiz-Hidalgo C, de Leon Bojorge B, Albores Saavedra J. Stromal tumor of the gallblader with phenotype of interstitial cells of Cajal. A previous unrecognized neoplasm. Am J Surg Pathol 2000: 24: 1420-1423. [CrossRef] Zhao WY,